How to get over with medication errors underestimation? Improving indices of medication errors with focus on intravenous medications in hematopoietic stem cell transplantation setting; a direct observation study.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 26 06 2023
accepted: 05 07 2024
medline: 22 8 2024
pubmed: 22 8 2024
entrez: 22 8 2024
Statut: epublish

Résumé

The administration of intravenous (IV) medications is a technically complicated and error-prone process. Especially, in the hematopoietic stem cell transplantation (HSCT) setting where toxic drugs are frequently used and patients are in critical immunocompromised conditions, medication errors (ME) can have catastrophic reactions and devastating outcomes such as death. Studies on ME are challenging due to poor methodological approaches and complicated interpretations. Here, we tried to resolve this problem using reliable methods and by defining new denominators, as a crucial part of an epidemiological approach. This was an observational, cross-sectional study. A total of 525 episodes of IV medication administration were reviewed by a pharmacist using the disguised direct observation method to evaluate the preparation and administration processes of 32 IV medications in three HSCT wards. We reported errors in 3 ratios; 1) Total Opportunities for Error (TOE; the number of errors/sum of all administered doses observed plus omitted medications), 2) Proportional Error Ratio (the number of errors for each drug or situation/total number of detected errors) and, 3) Corrected Total Opportunities for Errors (CTOE; the number of errors/ Sum of Potential Errors (SPE)). A total of 1,568 errors were observed out of 5,347 total potential errors. TOE was calculated as 2.98 or 298% and CTOE as 29.3%. Most of the errors occurred at the administration step. The most common potential errors were the use of an incorrect volume of the reconstitution solvent during medication preparation and lack of monitoring in the administration stage. Medication errors frequently occur during the preparation and administration of IV medications in the HSCT setting. Using precise detection methods, denominators, and checklists, we identified the most error-prone steps during this process, for which there is an urgent need to implement effective preventive measures. Our findings can help plan targeted preventive measures and investigate their effectiveness, specifically in HSCT settings.

Sections du résumé

BACKGROUND BACKGROUND
The administration of intravenous (IV) medications is a technically complicated and error-prone process. Especially, in the hematopoietic stem cell transplantation (HSCT) setting where toxic drugs are frequently used and patients are in critical immunocompromised conditions, medication errors (ME) can have catastrophic reactions and devastating outcomes such as death. Studies on ME are challenging due to poor methodological approaches and complicated interpretations. Here, we tried to resolve this problem using reliable methods and by defining new denominators, as a crucial part of an epidemiological approach.
METHODS METHODS
This was an observational, cross-sectional study. A total of 525 episodes of IV medication administration were reviewed by a pharmacist using the disguised direct observation method to evaluate the preparation and administration processes of 32 IV medications in three HSCT wards. We reported errors in 3 ratios; 1) Total Opportunities for Error (TOE; the number of errors/sum of all administered doses observed plus omitted medications), 2) Proportional Error Ratio (the number of errors for each drug or situation/total number of detected errors) and, 3) Corrected Total Opportunities for Errors (CTOE; the number of errors/ Sum of Potential Errors (SPE)).
RESULTS RESULTS
A total of 1,568 errors were observed out of 5,347 total potential errors. TOE was calculated as 2.98 or 298% and CTOE as 29.3%. Most of the errors occurred at the administration step. The most common potential errors were the use of an incorrect volume of the reconstitution solvent during medication preparation and lack of monitoring in the administration stage.
CONCLUSION CONCLUSIONS
Medication errors frequently occur during the preparation and administration of IV medications in the HSCT setting. Using precise detection methods, denominators, and checklists, we identified the most error-prone steps during this process, for which there is an urgent need to implement effective preventive measures. Our findings can help plan targeted preventive measures and investigate their effectiveness, specifically in HSCT settings.

Identifiants

pubmed: 39173064
doi: 10.1371/journal.pone.0307753
pii: PONE-D-23-13349
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0307753

Informations de copyright

Copyright: © 2024 Mansouri et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Eur J Hosp Pharm. 2020 Jan;27(1):3-8
pubmed: 32064081
Am J Health Syst Pharm. 2018 Oct 1;75(19):1493-1517
pubmed: 30257844
BMC Health Serv Res. 2012 Mar 12;12:60
pubmed: 22409837
Pharm World Sci. 2003 Dec;25(6):264-8
pubmed: 14689814
Br J Clin Pharmacol. 2009 Jun;67(6):614-20
pubmed: 19594528
Arch Intern Med. 2002 Sep 9;162(16):1897-903
pubmed: 12196090
Eur J Cancer Care (Engl). 2018 Jul;27(4):e12863
pubmed: 29873424
Eur J Cancer Care (Engl). 2010 May;19(3):285-92
pubmed: 19708929
Lancet Oncol. 2018 Apr;19(4):e191-e199
pubmed: 29611527
Eur J Clin Pharmacol. 2013 Apr;69(4):995-1008
pubmed: 23090705
Cancer Chemother Pharmacol. 1992;31(3):171-81
pubmed: 1464154
Res Social Adm Pharm. 2022 Jan;18(1):2164-2169
pubmed: 34147371
Int J Nurs Stud. 2016 Jan;53:342-50
pubmed: 26365701
Am J Health Syst Pharm. 2002 Mar 1;59(5):436-46
pubmed: 11887410
BMC Nurs. 2015 Oct 21;14:53
pubmed: 26500449
Drug Saf. 2013 Nov;36(11):1045-67
pubmed: 23975331
Med J Malaysia. 2013;68(1):52-7
pubmed: 23466768
Psychiatr Serv. 2003 May;54(5):677-81
pubmed: 12719497
Int J Qual Health Care. 2010 Dec;22(6):507-18
pubmed: 20956285
Ann Pharmacother. 2013 Feb;47(2):237-56
pubmed: 23386063
J Oncol Pharm Pract. 2019 Oct;25(7):1665-1674
pubmed: 30348073
BMJ Qual Saf. 2013 Apr;22(4):278-89
pubmed: 23322752
Qual Saf Health Care. 2005 Jun;14(3):190-5
pubmed: 15933316
Qual Saf Health Care. 2003 Dec;12 Suppl 2:ii8-12
pubmed: 14645889
Int J Qual Health Care. 2005 Feb;17(1):15-22
pubmed: 15668306
Crit Care Med. 2010 Dec;38(12):2275-81
pubmed: 20838333
Yakugaku Zasshi. 2014;134(8):909-14
pubmed: 25088322
Am J Health Syst Pharm. 2009 Jul 1;66(13):1202-10
pubmed: 19535659
Cancer Nurs. 2019 Sep/Oct;42(5):365-372
pubmed: 29863578
Qual Saf Health Care. 2010 Aug;19(4):341-5
pubmed: 20065297
Daru. 2013 Jun 20;21(1):49
pubmed: 23787134
BMJ. 2003 Mar 29;326(7391):684
pubmed: 12663404
J Clin Pharm Ther. 2009 Apr;34(2):215-23
pubmed: 19250142
Iran J Pharm Res. 2015 Winter;14(Suppl):87-93
pubmed: 26185509

Auteurs

Ava Mansouri (A)

Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran.

Kiana Moazzeni (K)

Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Maryam Valeh (M)

Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran.

Kazem Heidari (K)

Clinical Trial Center, Tehran University of Medical Sciences, Tehran, Iran.

Molouk Hadjibabaie (M)

Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran.
Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH